Karyopharm (KPTI) Sell-Off Overdone, Leerink Partners Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 7:30 AM EDTPositive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers
Provides Update to Certain Trials based on Expanding Clinical Experience
Conference Call Scheduled for today at 8:30 a.m. ET
NEWTON, Mass., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"Important data describing the clinical benefit of selinexor across multiple solid and hematologic malignancies was... More
